Table 1

Patient characteristics at 6-month echocardiographic follow-up

VariableNo reduction in LAD (n=275)Reduction in LAD (n=398)P valueNumber of patients analysed
Clinical characteristics
 Age (years)76.1±11.674.2±12.60.07673
 Age≥80 years*130 (47%)154 (39%)0.03673
 Women*130 (47%)165 (41%)0.14673
 BMI (kg/m2)23.0±5.122.5±4.40.64506
 BMI≤22 kg/m2107 (50%)144 (49%)0.81506
Medical history
 Atrial fibrillation or flutter*156 (57%)222 (56%)0.81673
 Hypertension212 (77%)287 (72%)0.15673
 Diabetes115 (42%)141 (35%)0.09673
 Previous myocardial infarction69 (25%)79 (20%)0.11673
Tests at 6-month follow-up
 BNP (pg/mL)224.1 (114.4–435.5)153.9 (63.3–312.0)0.0002507
 eGFR (mL/min/1.73 m2)43.4±19.446.5±20.80.06642
 eGFR <30 mL/min/1.73 m2*71 (27%)86 (23%)0.23642
 Albumin (g/dL)3.9±0.463.9±0.570.24608
 Albumin <3 g/dL7 (2.8%)16 (4.5%)0.26608
 Haemoglobin (g/L)118±22121±230.03638
 Anaemia *169 (64%)208 (56%)0.03638
Medications at 6-month follow-up
 ACE-I or ARB*139 (60%)194 (62%)0.70545
 β-blocker*181 (78%)249 (79%)0.79545
 MRA*104 (45%)142 (45%)1.0544
 Diuretic198 (85%)259 (82%)0.33547
  • Diuretics included loop diuretic, thiazide and tolvaptan.

  • *Risk-adjusting variables selected for the Cox proportional hazards regression model.

  • ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; LAD, left atrial diameter; MRA, mineralocorticoid receptor antagonist.